Physician profile
Daniel Nazon
NPI 1386676476
$2,044.04
in general payments reported to CMS, 2019-2025
26 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $89.58 · 2021: $44.97 · 2022: $517 · 2023: $619 · 2024: $236 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $670.71 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $192.63 | 2019-2023 | Nucala |
| Mylan Specialty L.P. | $179.57 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.09 | 2020-2024 | Jardiance, Ofev |
| Insmed, INC. | $90.69 | 2019-2025 | Arikayce |
| Philips North America LLC | $70.25 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $56.22 | 2023 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $56.18 | 2022-2023 | Eliquis |
| Grifols USA, LLC | $53.16 | 2020-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $52.15 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.66 | 2022-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $50.35 | 2022-2023 | Verquvo |
| Inogen, INC. | $49.95 | 2022-2024 | |
| Boston Scientific Corporation | $40.52 | 2022 | |
| Mallinckrodt Hospital Products INC. | $33.02 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30.05 | 2025 | |
| Pulmonx Corporation | $27.48 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Verona Pharma, INC. | $27.37 | 2025 | Ohtuvayre |
| Irhythm Technologies, INC. | $25.35 | 2023 | Zio Xt Patch |
| Viatris Specialty LLC | $24.90 | 2025 | Yupelri |
| Ambu INC. | $18.58 | 2023 | |
| Janssen Pharmaceuticals, INC | $17.78 | 2023 | Xarelto |
| Baxter Healthcare | $16.70 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Tactile Systems Technology INC | $16.37 | 2023 | Flexitouch Plus, Entre Plus |
| Pfizer INC. | $14.23 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $13.08 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Nazon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.